Novotech

Basic Info

Novotech is a globally recognized full-service clinical research organization (CRO)

and scientific advisory company that provides biotech and small- to mid-sized

pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.

Novotech leverages its therapeutic and regulatory expertise, client-centric service

model, local market insights, and advanced analytical tools to expedite patient

recruitment, enhance trial efficiencies, and bring life-changing therapies to market

faster. This work has been recognized by awards such as the Frost & Sullivan CRO

Company of the Year, which Novotech has received for 19 consecutive years.

Why work with us

Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.

Through its client-centric service model, Novotech seamlessly integrates people,

processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies.

By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.

Brochure

Company focus

Services

Contact Research Organisation (CRO)

Industries

Biotechnology

Projects or Case studies (2)

A Nimble and Flexible Solution to Rescuing an Observational Study Accelerated site start-up and exceeding patient recruitment in APAC

European Biotech focused on developing therapies for cancer patients. The observational retrospective study of therapies for relapsed or refractory diffuse large B cell lymphoma was facing recruitment challenges across the 145+ sites in North America and Europe. Objective: To facilitate rapid study start-up of APAC sites and recruitment of 500 patients to expedite the study’s global recruitment milestone and meet FDA submission deadline. Strategy: Commenced expansion in Australia to take advantage of the country’s pragmatic regulatory pathway supporting accelerated study start-up of 9 sites. In parallel, Novotech’s extensive site and PI relationships were leveraged to achieve rapid start-up of 6 sites in South Korea and 3 sites in Taiwan. The first site (in South Korea) was activated only 1.5 months after EC submission. APAC site patient recruitment was not only achieved but exceeded (547 vs 500).

Phase 1a and 1b data for oncolytic immunotherapy sponsor across 6 sites in Australia

The Sponsor is a specialized biotech company based in Australia specializing in the development of a novel oncolytic immunotherapy that targets cancer indications. The Sponsor contracted Novotech for full-service activities (Clinical, Reg, PV, DM, MM and CSUR) on their Phase I a & b clinical trial. 6 sites across Australia. Started in 2022, end estimated to be complete by Q4 2026; Phase 1a ongoing; Phase Ib starting in Sept 2024. Protocol to follow GCP and regulatory standards, achieve recruitment targets, and submit an FDA IND. The sponsor is pleased with Novotech’s achievement of current study milestones.

Contacts

Nick Rich

Regional Director Business Development